Skip to main content
Top
Published in: Pediatric Nephrology 6/2013

01-06-2013 | Original Article

Preoperative plasma FGF23 levels predict acute kidney injury in children: results of a pilot study

Authors: Farah N. Ali, Amanda Hassinger, Heather Price, Craig B. Langman

Published in: Pediatric Nephrology | Issue 6/2013

Login to get access

Abstract

Background

Acute kidney injury (AKI) carries a large burden of morbidity and mortality. Early diagnosis may lead to better strategies of clinical care. Cardiac surgery involving cardiopulmonary bypass is associated with a significant incidence of AKI. The study objective was to determine whether or not preoperative fibroblast growth factor-23 (FGF23) levels differed among pediatric patients who did or did not develop AKI following cardiac surgery.

Methods

A nested case–control study was performed. FGF23 levels were measured pre- and post-operatively in 19 children without chronic kidney disease (CKD) who underwent cardiopulmonary bypass. Five patients developed AKI and 14 patients served as controls.

Results

FGF23 levels in patients who developed AKI following cardiac surgery were elevated above normal levels, both pre-operatively and post-operatively compared with those patients who did not develop AKI. Relative risk of developing AKI when the pre-operative FGF23 level was >86 RU/mL was 2.0 (p = 0.033). Preoperative FGF23 levels correlated with post-operative fluid gain (correlation coefficient 0.607, p = 0.0059).

Conclusions

FGF23 may serve as a pre-operative prognostic indicator of the development of AKI following cardiopulmonary bypass surgery in pediatric patients without CKD. Identifying patients more likely to have AKI following surgery provides a means of achieving closer clinical management of AKI and fluid balance.
Literature
1.
go back to reference Jo S, Rosner M, Okusa M (2007) Pharmacologic treatment of acute kidney injury: why drugs haven’t worked and what is on the horizon. Clin J Am Soc Nephrol 2:356–365PubMedCrossRef Jo S, Rosner M, Okusa M (2007) Pharmacologic treatment of acute kidney injury: why drugs haven’t worked and what is on the horizon. Clin J Am Soc Nephrol 2:356–365PubMedCrossRef
3.
4.
go back to reference Devarajan P (2005) Cellular and molecular derangements in acute tubular necrosis. Curr Opin Pediatr 17:193–199PubMedCrossRef Devarajan P (2005) Cellular and molecular derangements in acute tubular necrosis. Curr Opin Pediatr 17:193–199PubMedCrossRef
5.
go back to reference Symons J, Chua A, Somers M, Baum M, Bunchman T, Benfield M, Brophy P, Blowey D, Fortenberry J, Chand D, Flores F, Hackbarth R, Alexander S, Mahan J, McBryde K, Goldstein S (2007) Demographic characteristics of pediatric continuous renal replacement therapy: a report of the prospective pediatric continuous renal replacement therapy registry. Clin J Am Soc Nephrol 2:732–738PubMedCrossRef Symons J, Chua A, Somers M, Baum M, Bunchman T, Benfield M, Brophy P, Blowey D, Fortenberry J, Chand D, Flores F, Hackbarth R, Alexander S, Mahan J, McBryde K, Goldstein S (2007) Demographic characteristics of pediatric continuous renal replacement therapy: a report of the prospective pediatric continuous renal replacement therapy registry. Clin J Am Soc Nephrol 2:732–738PubMedCrossRef
6.
go back to reference Ali F, Lane J (2012) Hemofiltration circuit use beyond 72 hours in pediatric continuous renal replacement therapy. Int J Artif Organs 35:139–143PubMed Ali F, Lane J (2012) Hemofiltration circuit use beyond 72 hours in pediatric continuous renal replacement therapy. Int J Artif Organs 35:139–143PubMed
7.
go back to reference Goldstein S, Currier H, Graf C, Cosio C, Brewer E, Sachdeva R (2001) Outcome in children receiving continuous venovenous hemofiltration. Pediatrics 107:1309–1312PubMedCrossRef Goldstein S, Currier H, Graf C, Cosio C, Brewer E, Sachdeva R (2001) Outcome in children receiving continuous venovenous hemofiltration. Pediatrics 107:1309–1312PubMedCrossRef
8.
go back to reference Goldstein S, Somers M, Baum M, Symons J, Brophy P, Blowey D, Bunchman T, Baker C, Mottes T, McAfee N, Barnett J, Morrison G, Rogers K, Fortenberry J (2005) Pediatric patients with multi-organ dysfunction syndrome receiving continuous renal replacement therapy. Kidney Int 67:653–658PubMedCrossRef Goldstein S, Somers M, Baum M, Symons J, Brophy P, Blowey D, Bunchman T, Baker C, Mottes T, McAfee N, Barnett J, Morrison G, Rogers K, Fortenberry J (2005) Pediatric patients with multi-organ dysfunction syndrome receiving continuous renal replacement therapy. Kidney Int 67:653–658PubMedCrossRef
9.
go back to reference Fargason C, Langman C (1993) Limitations of the pediatric risk of mortality score in assessing children with acute renal failure. Pediatr Nephrol 7:703–707PubMedCrossRef Fargason C, Langman C (1993) Limitations of the pediatric risk of mortality score in assessing children with acute renal failure. Pediatr Nephrol 7:703–707PubMedCrossRef
11.
go back to reference Coca S, Yusuf B, Shlipak M, Garg A, Parikh C (2009) Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 53:961–973PubMedCrossRef Coca S, Yusuf B, Shlipak M, Garg A, Parikh C (2009) Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 53:961–973PubMedCrossRef
12.
go back to reference Gutierrez O, Januzzi J, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang T, deFilippi C, Wolf M (2009) Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119:2545–2552PubMedCrossRef Gutierrez O, Januzzi J, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang T, deFilippi C, Wolf M (2009) Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119:2545–2552PubMedCrossRef
13.
go back to reference Jean G, Terrat J, Vanel T, Hurot J, Lorriaux C, Mayor B, Chazot C (2009) High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 24:2792–2796PubMedCrossRef Jean G, Terrat J, Vanel T, Hurot J, Lorriaux C, Mayor B, Chazot C (2009) High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 24:2792–2796PubMedCrossRef
14.
go back to reference Liu P, Bai X, Wang H, Karaplis A, Goltzman D, Miao D (2009) Hypophosphatemia-mediated hypotension in transgenic mice overexpressing human FGF-23. Am J Physiol Heart Circ Physiol 297:H1514–H1520PubMedCrossRef Liu P, Bai X, Wang H, Karaplis A, Goltzman D, Miao D (2009) Hypophosphatemia-mediated hypotension in transgenic mice overexpressing human FGF-23. Am J Physiol Heart Circ Physiol 297:H1514–H1520PubMedCrossRef
15.
go back to reference Gutierrez O, Mannstadt M, Isakova T, Rauh-Hain J, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359:584–592PubMedCrossRef Gutierrez O, Mannstadt M, Isakova T, Rauh-Hain J, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359:584–592PubMedCrossRef
16.
go back to reference Hassinger A, Backer C, Lane J, Haymond S, Wang D, Wald E (2012) Predictive power of serum cystatin C to detect acute kidney injury and pediatric-modified RIFLE class in children undergoing cardiac surgery. Pediatr Crit Care Med 13:435–440PubMedCrossRef Hassinger A, Backer C, Lane J, Haymond S, Wang D, Wald E (2012) Predictive power of serum cystatin C to detect acute kidney injury and pediatric-modified RIFLE class in children undergoing cardiac surgery. Pediatr Crit Care Med 13:435–440PubMedCrossRef
17.
go back to reference Isakova T, Wahl P, Vargas G, Gutierrez O, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend R, Anderson C, Lash J, Hsu C, Leonard M, Wolf M (2011) Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79:1370–1378PubMedCrossRef Isakova T, Wahl P, Vargas G, Gutierrez O, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend R, Anderson C, Lash J, Hsu C, Leonard M, Wolf M (2011) Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79:1370–1378PubMedCrossRef
18.
go back to reference Zhang M, Hsu R, Hsu C, Kordesch K, Nicasio E, Cortez A, McAlpine I, Brady S, Zhuo H, Kangelaris K, Stein J, Calfee C, Liu K (2011) FGF-23 and PTH levels in patients with acute kidney injury: a cross-sectional case series study. Ann Intensive Care 1:21PubMedCrossRef Zhang M, Hsu R, Hsu C, Kordesch K, Nicasio E, Cortez A, McAlpine I, Brady S, Zhuo H, Kangelaris K, Stein J, Calfee C, Liu K (2011) FGF-23 and PTH levels in patients with acute kidney injury: a cross-sectional case series study. Ann Intensive Care 1:21PubMedCrossRef
19.
go back to reference Leaf D, Wolf M, Waikar S, Chase H, Christov M, Cremers S, Stern L (2012) FGF-23 levels in patients with AKI and risk of adverse outcomes. Clin J Am Soc Nephrol 7:1217–1223PubMedCrossRef Leaf D, Wolf M, Waikar S, Chase H, Christov M, Cremers S, Stern L (2012) FGF-23 levels in patients with AKI and risk of adverse outcomes. Clin J Am Soc Nephrol 7:1217–1223PubMedCrossRef
Metadata
Title
Preoperative plasma FGF23 levels predict acute kidney injury in children: results of a pilot study
Authors
Farah N. Ali
Amanda Hassinger
Heather Price
Craig B. Langman
Publication date
01-06-2013
Publisher
Springer-Verlag
Published in
Pediatric Nephrology / Issue 6/2013
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-012-2395-2

Other articles of this Issue 6/2013

Pediatric Nephrology 6/2013 Go to the issue